Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Viking Therapeutics, Inc. - Common Stock (NQ: VKTX )

30.92 +1.19 (+4.00%)
Streaming Delayed Price Updated: 11:29 AM EDT, Mar 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Viking Therapeutics, Inc. - Common Stock

< Previous 1 2
...
10 11 12 13 14 15 16 17 18
...
22 23 Next >
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Viking Therapeutics Unusual Options Activity For March 19
Via Benzinga
Warning: This Skyrocketing Stock Has a Hidden Risk
Don't bet on this pitfall happening, but know that it's a possibility. 
Via The Motley Fool
Where Will Viking Therapeutics Be in 5 Years?
Expectations for the stock are high, and it could well deliver. 
Via The Motley Fool
Madrigal Pharmaceuticals Wins Approval for the First Drug Targeting the Multibillion-Dollar NASH Market. Is the Stock a Screaming Buy?
Madrigal's Rezdiffra will have the NASH market all to itself -- at least for a while. 
Via The Motley Fool
Will Viking Therapeutics Get Acquired?
Would an acquisition be good news for Viking Therapeutics investors? 
Via The Motley Fool
Check Out What Whales Are Doing With VKTX
Via Benzinga
Peering Into Viking Therapeutics's Recent Short Interest
Via Benzinga
If You Invested $100 In This Stock 5 Years Ago, You Would Have $900 Today
Via Benzinga
2 Stocks That Have More Than Tripled This Year: Are They Buys?
Don't jump on the bandwaggon too quickly. 
Via The Motley Fool
Should Pfizer Acquire Viking Therapeutics to Take on Eli Lilly and Novo Nordisk in the Obesity Drug Market?
Viking Therapeutics just might be an attractive acquisition target for Pfizer. 
Via The Motley Fool
7 Biotech Stocks to Buy as Sector Rotation Ramps Up
With digital innovation possibly getting overextended, now’s the time to consider biotech stocks for an incoming rotation. 
Via InvestorPlace
Unleashing the Bulls: 3 Top Stocks to Charge Ahead in March
This environment presents a compelling opportunity for investors seeking growth. Discover 3 top stocks primed for long-term growth in 2024. 
Via InvestorPlace
Could Viking Therapeutics Challenge Giant Eli Lilly in the Billion-Dollar Weight-Loss Drug Market?
Viking aims to enter a market that may be worth $100 billion in a few years. 
Via The Motley Fool
Is Viking Therapeutics Stock a Buy?
Its potential is looking increasingly more likely to be realized. 
Via The Motley Fool
1 Big New Reason to Buy Novo Nordisk Stock Hand Over Fist Right This Instant
The pharma giant could have yet another knockout obesity drug on the way. 
Via The Motley Fool
What's Going On With Viking Therapeutics (VKTX) Stock?
Viking Therapeutics shares are trading lower by 10.9% Monday afternoon. The stock has experienced marked volatility following a number of key company announcements in February. 
Via Benzinga
Missed Out on Eli Lilly and Novo Nordisk? This Could Be the Next Big Weight Loss Stock.
Viking Therapeutics has a promising anti-obesity treatment that is generating a lot of interest. 
Via The Motley Fool
3 Stock Winners That Are Up 1,000% or More in 2024
Dig deep enough, and find a story hot enough, and you can uncover potential stock winners up 1,000%. Here are three. 
Via InvestorPlace
9 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Why HighPeak Energy Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of HighPeak Energy, Inc. (NASDAQ: HPK) fell sharply during Thursday’s session after the company reported worse-than-expected fourth-quarter revenue results. 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Why Viking Therapeutics Stock Is Plunging Today
The sell-off could present a buying opportunity for aggressive investors willing to bet that the obesity market will be big enough for multiple winners. 
Via The Motley Fool
Novo Nordisk Jumps On Strong Results For New Weight-Loss Drug
Amycretin showed a 13.1% weight loss after 12 weeks in a phase 1 trial. 
Via Investor's Business Daily
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Vivani Medical Surges on its Ozempic-Like Weight-Loss Implant
The Ozempic craze continues to make headlines in the medical sector, and GLP-1 drug stocks such as Vivani Medical continue to surge higher 
Via MarketBeat
Exposures Product Safety
Is Viking Therapeutics Stock a Better Buy Than Eli Lilly and Novo Nordisk After the Latest Weight-Loss Drug News?
A new player in the multibillion-dollar weight-loss drug market could be waiting in the wings. 
Via The Motley Fool
A New Competitor to Wegovy Could Be on the Way. Should Novo Nordisk Be Worried?
Here's why I'm not worried. 
Via The Motley Fool
Better Weight Loss Drug Stock: Viking Therapeutics vs. Eli Lilly
One is a reigning champion, and the other is a burgeoning contender. 
Via The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
< Previous 1 2
...
10 11 12 13 14 15 16 17 18
...
22 23 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.